2.1
Nivolumab (Opdivo, Bristol-Myers Squibb) with chemotherapy is indicated for 'the neoadjuvant treatment of resectable (tumours ≥ 4 cm or node positive) non-small cell lung cancer in adults'.
2 Information about nivolumab with chemotherapy
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for nivolumab.
Price
2.3
The list price for nivolumab is £439.00 for a (10 mg/ml) 4‑ml vial (excluding VAT; BNF online, accessed January 2023).
2.4
The company has a commercial arrangement. This makes nivolumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.